Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but does not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy

• Ngā kaituhi matua: Nicholas Funderburg (Author), Morgan Boucher (Author), Abdus Sattar (Author), Manjusha Kulkarni (Author), Danielle Labbato (Author), Bruce I. Kinley (Author), Grace A. McComsey (Author)
• Hōputu: Pukapuka
• I whakaputaina: Case Western Reserve University, 2016-07-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Introduction: Altered gastrointestinal (GI) barrier integrity and subsequent microbial translocation may contribute to immune activation in HIV infection. We have reported that rosuvastatin improved several markers of immune activation in HIV+ participants, but the effect of statin treatment on mark...